# Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

> **NCT04220073** · PHASE1 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005

## Interventions

- **BIOLOGICAL:** JS005 (recombinant humanized monoclonal antibody against IL-17A)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04220073
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-05
- **Primary completion:** 2020-09-21
- **Final completion:** 2021-01-17
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04220073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04220073, "Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04220073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*